Lenabasum 20 mg
JBT101-DM-002
Phase 3 small_molecule completed
Quick answer
Lenabasum 20 mg for Dermatomyositis is a Phase 3 program (small_molecule) at Corbus Pharmaceuticals Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Corbus Pharmaceuticals Holdings
- Indication
- Dermatomyositis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed